title: The role of patient satisfaction in methadone treatment.
abstract: BACKGROUND
  Patient satisfaction surveys, widely used in health care delivery systems, may provide useful data for improving patient retention and outcomes.
  
  
  OBJECTIVE
  This study examined the relationship between methadone patients' treatment satisfaction at three months post-admission and their 3-month treatment outcomes and 12-month treatment retention.
  
  
  METHODS
  New methadone treatment admissions (N = 283) were assessed at 3 months post-admission for satisfaction with their counselors and programs. Correlations examined the relationship between 3-month satisfaction and Addiction Severity Index (ASI) scores. Regression analysis assessed the relationship between satisfaction and drug testing at 3 months and was used to predict whether participants were retained in treatment at 12 months.
  
  
  RESULTS
  Participants who were more satisfied with their counselors and programs had lower Drug and Legal ASI composite scores at 3 months. Participants who were more satisfied with their programs remained in treatment for at least 12 months.
  
  
  CONCLUSIONS
  Treatment programs should consider administering the CEF to their patients at 3 months post-admission to identify patients with low satisfaction scores who may be at risk for prematurely leaving treatment.
  
  
  CONCLUSIONS
  Measuring patient satisfaction during treatment may help programs meet patients' needs and improve retention.
authors.affiliation: Friends Research Institute, Inc., Baltimore, Maryland, USA. skelly@friendsresearch.org
authors.forename: Sharon M
authors.initials: SM
authors.lastname: Kelly
authors.forename: Kevin E
authors.initials: KE
authors.lastname: O'Grady
authors.forename: Barry S
authors.initials: BS
authors.lastname: Brown
authors.forename: Shannon Gwin
authors.initials: SG
authors.lastname: Mitchell
authors.forename: Robert P
authors.initials: RP
authors.lastname: Schwartz
mesh_terms: D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D019538:Health Care Surveys; D006801:Humans; D008297:Male; D008691:Methadone / Q000627:therapeutic use*; D009294:Narcotics / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000523:psychology / Q000534:rehabilitation*; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D012044:Regression Analysis; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D009294:Narcotics; D008691:Methadone
references.citation: J Subst Abuse Treat. 2004 Sep;27(2):99-121
references.pmid: 15450644
references.citation: J Behav Health Serv Res. 2002 Aug;29(3):345-56
references.pmid: 12216378
references.citation: Drug Alcohol Rev. 2008 Mar;27(2):138-44
references.pmid: 18264873
references.citation: Drug Alcohol Rev. 2008 Nov;27(6):671-8
references.pmid: 19378450
references.citation: J Subst Abuse Treat. 2002 Jun;22(4):183-96
references.pmid: 12072163
references.citation: Am J Drug Alcohol Abuse. 2009;35(1):38-42
references.pmid: 19152205
references.citation: Milbank Q. 1996;74(1):51-85
references.pmid: 8596524
references.citation: Addiction. 2000 Nov;95 Suppl 3:S347-60
references.pmid: 11132362
references.citation: J Subst Abuse Treat. 1992;9(3):199-213
references.pmid: 1334156
references.citation: Am J Psychiatry. 1995 Sep;152(9):1302-8
references.pmid: 7653685
references.citation: Am J Drug Alcohol Abuse. 2008;34(1):17-28
references.pmid: 18161640
references.citation: J Subst Abuse Treat. 1997 Nov-Dec;14(6):565-72
references.pmid: 9437628
references.citation: J Health Psychol. 2008 Apr;13(3):388-400
references.pmid: 18420772
references.citation: J Subst Abuse. 1995;7(1):117-34
references.pmid: 7655308
references.citation: Health Mark Q. 2007;24(1-2):93-106
references.pmid: 19042522
references.citation: Drug Alcohol Depend. 2005 Sep 1;79(3):405-12
references.pmid: 15869846